DSM-Firmenich, a Swiss-French specialty chemicals company specializing in aromas, fragrances, and health products, has formed a strategic partnership with Boltz, a KI-driven start-up founded by former researchers from the Massachusetts Institute of Technology (MIT). The collaboration aims to leverage Boltz’s AI models for biomolecular modeling, enhancing DSM’s ability to discover novel molecules for next-generation fragrances and aromas.
Under the agreement, Boltz’s proprietary baseline models will be integrated into DSM’s internal discovery process. These AI tools will combine with DSM’s extensive database of sensory receptor data—covering taste and odor interactions—to predict and design molecular structures. The goal is to improve understanding of how molecules interact with specialized proteins and how these interactions translate into sensory signals for the brain.
Boltz has previously partnered with pharmaceutical giants Pfizer, Takeda, and GSK, indicating a track record in applying AI to drug and ingredient discovery. DSM-Firmenich’s shares have been listed on Euronext Amsterdam since April 18, 2023, reflecting the company’s long-standing presence in European capital markets.
